Industry / South Korea
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
CKD Pharm Concentrates On Novel Anticancer Drugs
February 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
South Korean drugmaker Chong Kun Dang Pharmaceutical (CKD Pharm) wants to develop more original pharmaceuticals, focusing on arguably the most lucrative therapeutic area, oncology. The company will increase the amount it spends on R&D and will continue to invest in its sales and marketing capabilities. Given the increasing strength of generic rivals and the erosion of its active pharmaceutical ingredient (API) business by low-cost competitors, BMI believes the strategy is a sound